What It’s Like to Be a Myeloma Millennial, Or, ‘Myelennial’

Video

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

The treatments for multiple myeloma have changed dramatically over the past decade, according to an expert at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

In an interview with CURE®, Dr. Nina Shah, an associate professor of clinical medicine, explained how the new drugs and tools used to treat multiple myeloma inspired her to coin the term “myelennial,” which is inspired by jokes frequently made by the millennial generation about certain characteristics and cultural norms of their age group.

“I have some criteria, like, ‘only looks at MRD data,’ you know, ‘thinks Durie-Salmon is a paint color at Sherwin Williams,’ and you know, ‘has never given thalidomide or oral melphalan,’” said Shah. “It’s the myeloma millennials. It’s not that I was actually born in the millennial generation, but as a myeloma doctor, I’m a millennial.”

Transcription:

You know the reason I call myself a “myelennial,” is that myeloma has absolutely dramatically changed in the past 10 to 15 years, but even in the last five years. And so, the things that we used to do, even actually before I was practicing myeloma, with melphalan and prednisone, that was it. And then there was thalidomide and now, I mean even lenalidomide, which was considered novel is actually not that novel anymore.

So, there are all these new drugs and the few tools we have, we have so many more of them now. So now I can say it's like the same thing as being a millennial. It's like I have some criteria, like ‘only looks at MRD data,’ you know, ‘thinks Durie-Salmon is a paint color at Sherwin Williams,’ and you know, ‘has never given thalidomide or oral melphalan,’ these things. It's the myeloma millennials. It's not that I was actually born in the millennial generation, but as a myeloma doctor I'm a millennial. I want answers and I want them right now, on an app!

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE